

Completion of Phase 2a clinical trial in Plaque Psoriasis

Release dated 21 June 2006

CBio has formally completed the first Phase 2a trial in Plaque Psoriasis in 24 patients.

The study was to assess efficacy and safety of Cpn10 when administered as twice weekly intravenous injections over 12 weeks in patients with moderate to severe psoriasis. The results in this exploratory study met set objectives. These results along with the results from the recently completed Rheumatoid Arthritis and Multiple Sclerosis studies confirm the high potential of CBio's product XToll™ (Chaperonin 10) in treating autoimmune and chronic inflammatory diseases.

XToll™ has been shown to work by a mode of action different to existing anti-TNF therapies and with a good safety profile.

The clinical trial was carried out in Melbourne (Dr Christopher McCormack, Cabrini Hospital).

CBio continues to progress the further commercial development of XToll™.

For further information please contact:

Dr Dennis Feeney
Chief Scientific Officer
Ph. 07 38414844
Fax 07 38418189
Mobile 0412617311

Dr Wolf Hanisch
Chief Executive Officer
Ph. 07 38414844
Fax 07 38418189
Mobile 0412339460

Contact:

85 Brandl Street
Brisbane Technology
Park
Eight Mile Plains
Qld 4113 Australia

PO Box 8104
Sunnybank Plaza
Sunnybank
Qld 4109 Australia

Ph: 61 7 3841 4844
Fax: 61 7 3841 8189

www.cbio.com.au

ABN: 76 094 730 417
ACN: 094 730 417